Hyatt Hotels Corporation vs Merck & Co., Inc. — how do they compare? Hyatt Hotels Corporation trades at $159.3 (market cap $14.81B), while Merck & Co., Inc. trades at $141.84 (market cap $352.29B). The key difference: Merck & Co., Inc. is far larger — about 23.8× Hyatt Hotels Corporation's market cap, and Merck & Co., Inc. pays the higher dividend (2.38%). Which is the better fit depends on your goals — on Pluang, investors hold Hyatt Hotels Corporation for 148 Days and Merck & Co., Inc. for 98 Days on average.
| H | MRK | |
|---|---|---|
Market Cap | $14.81B | $352.29B |
Volume | 588,239 | 6,348,796 |
Sector | Consumer Cyclical | Health |
52-Week High | $202.09 | $156.43 |
52-Week Low | $135.42 | $82.49 |
Typical Hold Time | 148 Days | 98 Days |
Enterprise Value | $18.71B | $399.05B |
Dividend Yield | 0.38% | 2.38% |
Signals from Pluang's Aura AI — not financial advice
Hyatt Hotels (H) trades at $157.14, down 1.24% on the day, with a bearish technical signal from moving averages but neutral oscillators. The stock shows mixed fundamentals: revenue grew to $7.10B in 2025, but net income was a loss of $52M, and valuation ratios like a P/E of 194 appear elevated. Recent news highlights expansion efforts, including a loyalty collaboration with Delta Air Lines and new hotel openings, signaling growth initiatives amid operational challenges.
The outlook for H is cautious; analyst consensus is a Moderate Buy with a $197.77 price target, but high debt levels and volatile profitability pose risks. Upside depends on sustained revenue growth and margin improvement, while downside risks include economic sensitivity and execution delays in new projects.
Merck (MRK) trades at $142.79, up 0.61% today, with a bearish technical signal but strong fundamental performance. The company reported revenue of $65.01B in 2025 with a net income margin of 28.07%, and recent quarterly EPS have consistently beaten expectations. Merck is actively expanding its pipeline through acquisitions, such as the pending $6.7B purchase of Terns Pharmaceuticals announced in April 2026.
The outlook is supported by solid profitability and analyst optimism, with a consensus price target of $158.78 implying upside. Key risks include integration challenges from acquisitions and competitive pressures in the oncology sector. Cash flow trends show variability, with a projected net cash outflow of $1.2B in 2026 due to significant investing activities.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Hyatt is an operator of 1,162 owned (5% of total rooms) and managed and franchise (95%) properties across roughly 20 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, and the wellness brand Miraval. Hyatt acquired Two Roads in November 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 66% Americas, 18% Asia-Pacific, and 16% rest of world.
Read more on H →Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →